PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
Expired
investment:
£136,827
Evaclite manufactures dynamic exit signs designed to make buildings safer and save lives. The company argues that its products are 77% more visible than conventional exit signs and reduces congestion at exits by 36%. The company received the 2018 FIREX - Fire Innovation of the Year Award. It also won the Safety and Health Excellence (SHE) Award in 2019 and 2020. Evaclite counts companies like Apple, CBRE, BBC, Melia, and MetroBank amongst its clients. The company has inquiries from over a dozen countries globally with a 12-month sales opportunity pipeline of over £1.5 million. It will use 60% of the investment to build its sales team, 28% to boost its inbound marketing campaign, 7% to develop additional intellectual property, and 5% towards overhead and general costs.
days to go:
Expired
investment:
£148,736
Nova is a Venture Capital (VC) company that endeavours to back brilliant people who want to build notable companies that will change the world. Nova provides funding, guidance, and workforce to startups and helps them become profitable enterprises. The company meets around 2000 potential founders every year and becomes a co-founder of 20+ startups that it finds hold promise. Nova has created over £100 million of shareholder value. It also asserts that the three-year survival rate of its portfolio companies stands at 46% as compared to market norms of around 8-10%. The company will use £1 million of new capital investment to bolster the growth of its operational capacity to enable more successful ventures with amazing founders. It will also use the investment to be listed on a public market within a 3-5 year timeframe.
days to go:
Expired
investment:
£1,013,560
Knoma is a payment solution that helps people looking to future-proof their career or move into new areas of work by eliminating the burden of upfront payment, and by removing the challenges of sourcing an appropriate course. Backed by a large European Venture Capital firm, Knoma enables lifelong learning as the global economy transitions to one where digital skills are essential for career success. All Knoma students can gain access up to £10,000 to pay for the course of their choice, which can be spread over 12 months with flexible repayments with no interest or fees applicable. The company has partnered with organisations like Codeclan, Wild Code School, Le Wagon, and Code Nation and has successfully secured £750,000 in funding from some of Europe's largest venture capital firms, namely, Global Founders Capital, and Rocket Internet. The company will utilise the investments to expand partnerships with tech and coding schools, test and deploy the Knoma app, unlock a £20 million debt facility to provide Knoma loans to its students, and scale the business on all verticals.
days to go:
Expired
investment:
£529,660
Fiinu are building a new digital bank. They intend to distrupt the financial services industry, whilst helping customers improve their lives through better banking and a people before profit ethos. Their goal is for customers to be in better financial shape after they join Fiinu. Fiinu is currently undergoing the Bank of England authorisation.
days to go:
Expired
investment:
£563,099
ShareProperty is a property crowdfunding platform that allows you, the investor to select your investment according to your own risk profile and required rate of return. ShareProperty allows you to build and manage your own property portfolio, hold your investment to term or resell on the ShareProperty trading exchange.
days to go:
Expired
investment:
£149,002
